Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.
Advertisement
Set Alert for Articles By Alex Shimmings

Latest From Alex Shimmings

Xenon Down On Novel Acne Treatment Failure

Xenon Pharmaceuticals' attempts to treat acne with a SCD-1 inhibitor have met with failure at the Phase II stage, casting doubt on the therapeutic strategy and wiping more than 50% of the company's share price.

Clinical Trials Research & Development

CHMP Opinions: Opdivo Sees Keytruda's Hodgkin's And Raises It Head & Neck

Merck & Co and Bristol Myers Squibb's rival anti-PD1 products continue their game of one-upmanship with each gaining a new indication in the latest round of EU CHMP opinions.

Approvals Drug Review

GSK, Regeneron and UK Biobank In Gene Sequencing Initiative

GlaxoSmithKline and the Regeneron Genetics Center have joined forces with the UK Biobank to sequence genes from its 500,000 participants in an effort to improve drug discovery and disease diagnosis. The first data are due within a year.

Deals Companies

Novartis Pursues Disease-Modifying Differentiator For Cosentyx In Psoriasis

New extension data suggesting that Novartis's IL-17A inhibitor Cosentyx could alter the course of disease in its lead indication of psoriasis could position the drug earlier in the treatment paradigm and please payers; the company has launched a new prospective study to see if the results hold true.

Clinical Trials Research & Development

The Decline And Fall Of The Pharma Pipeline

2016 saw a drop in the growth rates for both number of products in active development and in the number of companies in active R&D. The data from a new report from Pharmaprojects seem to point to an end to recent years of accelerated growth in the pipeline that followed five years of stagnation.

Research & Development Analysis

Circassia Builds US Respiratory Presence with AstraZeneca Deal

Circassia has put memories of last year's Cat-SPIRE disappointment firmly behind it with a new deal with AstraZeneca for Tudorza and Duaklir in COPD that will allow it to concentrate on boosting its respiratory franchise.

Deals Companies
See All
Advertisement
UsernamePublicRestriction

Register